查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1434560

抗病毒药物市场：按药物类型、治疗药物和最终用途划分 - 2024-2030 年全球预测

Antiviral Drugs Market by Drug Type (Branded Drugs, Generic Drugs), Therapeutics (Acquired Immunodeficiency Syndrome Therapeutics, Hepatitis (B & C) Therapeutics, Herpes Therapeutics), End Use - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年抗病毒药物市场规模为562.2亿美元，预计2024年将达到598.4亿美元，2030年将达到876.1亿美元，复合年增长率为6.54%。

全球抗病毒药物市场

主要市场统计
基准年[2023] 562.2亿美元
预测年份 [2024] 598.4亿美元
预测年份 [2030] 876.1亿美元
复合年增长率（%） 6.54%
抗病毒药物市场-IMG1

FPNV定位矩阵

FPNV定位矩阵对于评估抗病毒药物市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对抗病毒药物市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

该报告对以下几个方面提供了宝贵的见解：

1-市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2-市场开拓：我们深入研究利润丰厚的新兴市场，并分析它们在成熟细分市场中的渗透率。

3- 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4-竞争力评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5- 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1-抗病毒药物市场规模和预测是多少？

2-抗病毒药物市场预测期内需要考虑投资的产品、细分市场、应用和领域有哪些？

3-抗病毒药物市场的技术趋势和法律规范是什么？

4-抗病毒药物市场主要供应商的市场占有率是多少？

5-进入抗病毒药物市场的合适型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • HIV、肝炎和流感等病毒性疾病增加
      • 政府和私营部门在抗病毒药物开发方面的支出增加
      • 增加防毒程式和宣传活动的数量以提高客户意识
    • 抑制因素
      • 对抗病毒药物治疗成本上升和专利到期的担忧
    • 机会
      • 针对多种病毒感染疾病和疾病的疫苗生产的研究和开发
      • 用于爱滋病毒疫苗开发的多种配方
    • 任务
      • 同类疗法疗法等替代疗法的普及
  • 市场区隔分析
  • 市场趋势分析
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法律规范

第六章按药物类型分類的抗病毒药物市场

  • 品牌药品
  • 学名药

第七章依治疗方法分類的抗病毒药物市场

  • 后天免疫力缺乏症候群的治疗方法
  • 肝炎（乙型和丙型）治疗药物
  • 治疗疱疹的药
  • 流感治疗药物
  • 肺炎

第八章抗病毒药物市场：依最终用途

  • 门诊手术中心
  • 诊所
  • 医院

第九章美洲抗病毒药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区抗病毒药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲抗病毒药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争形势

  • FPNV定位矩阵
  • 市场占有率分析：主要企业
  • 主要企业竞争情境分析

第13章竞争产品组合

  • 主要公司简介
    • Abacus Bioscience Inc.
    • Abbott Laboratories
    • AbbVie Inc.
    • Antiva Biosciences, Inc.
    • AstraZeneca PLC
    • Aurobindo Pharma
    • Bristol-Myers Squibb Company
    • Chimerix Inc.
    • Cipla Limited
    • Dr. Reddy's Laboratories Ltd.
    • ENYO Pharma SA
    • F. Hoffmann-La Roche AG
    • Gilead Sciences, Inc.
    • GlaxoSmithKline PLC
    • Johnson & Johnson
    • Merck & Co., Inc.
    • Novartis AG
  • 主要产品系列

第十四章附录

  • 讨论指南
  • 关于许可证和定价
Product Code: MRR-4358BACA82C1

[180 Pages Report] The Antiviral Drugs Market size was estimated at USD 56.22 billion in 2023 and expected to reach USD 59.84 billion in 2024, at a CAGR 6.54% to reach USD 87.61 billion by 2030.

Global Antiviral Drugs Market

KEY MARKET STATISTICS
Base Year [2023] USD 56.22 billion
Estimated Year [2024] USD 59.84 billion
Forecast Year [2030] USD 87.61 billion
CAGR (%) 6.54%
Antiviral Drugs Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Antiviral Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antiviral Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Antiviral Drugs Market, highlighting leading vendors and their innovative profiles. These include Abacus Bioscience Inc., Abbott Laboratories, AbbVie Inc., Antiva Biosciences, Inc., AstraZeneca PLC, Aurobindo Pharma, Bristol-Myers Squibb Company, Chimerix Inc., Cipla Limited, Dr. Reddy's Laboratories Ltd., ENYO Pharma SA, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Inc., and Novartis AG.

Market Segmentation & Coverage

This research report categorizes the Antiviral Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug Type
    • Branded Drugs
    • Generic Drugs
  • Therapeutics
    • Acquired Immunodeficiency Syndrome Therapeutics
    • Hepatitis (B & C) Therapeutics
    • Herpes Therapeutics
    • Influenza Therapeutics
    • Pneumonia
  • End Use
    • Ambulatory Surgical Centres
    • Clinics
    • Hospitals
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Antiviral Drugs Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antiviral Drugs Market?

3. What are the technology trends and regulatory frameworks in the Antiviral Drugs Market?

4. What is the market share of the leading vendors in the Antiviral Drugs Market?

5. Which modes and strategic moves are suitable for entering the Antiviral Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Antiviral Drugs Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing occurrence of viral diseases such as HIV, hepatitis, and influenza
      • 5.1.1.2. Rising government and private sector expenditure in the development of antiviral drugs
      • 5.1.1.3. Growing number of antiviral programs and campaigns to increase customer awareness
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of antiviral drug treatment and concerns of patent expiration
    • 5.1.3. Opportunities
      • 5.1.3.1. Research and development in the production of vaccines for numerous viral infections and diseases
      • 5.1.3.2. Extensive formulations to develop HIV vaccines
    • 5.1.4. Challenges
      • 5.1.4.1. Prevalence of alternative therapy such as homeopathy
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Antiviral Drugs Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Branded Drugs
  • 6.3. Generic Drugs

7. Antiviral Drugs Market, by Therapeutics

  • 7.1. Introduction
  • 7.2. Acquired Immunodeficiency Syndrome Therapeutics
  • 7.3. Hepatitis (B & C) Therapeutics
  • 7.4. Herpes Therapeutics
  • 7.5. Influenza Therapeutics
  • 7.6. Pneumonia

8. Antiviral Drugs Market, by End Use

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centres
  • 8.3. Clinics
  • 8.4. Hospitals

9. Americas Antiviral Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Antiviral Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Antiviral Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. Abacus Bioscience Inc.
    • 13.1.2. Abbott Laboratories
    • 13.1.3. AbbVie Inc.
    • 13.1.4. Antiva Biosciences, Inc.
    • 13.1.5. AstraZeneca PLC
    • 13.1.6. Aurobindo Pharma
    • 13.1.7. Bristol-Myers Squibb Company
    • 13.1.8. Chimerix Inc.
    • 13.1.9. Cipla Limited
    • 13.1.10. Dr. Reddy's Laboratories Ltd.
    • 13.1.11. ENYO Pharma SA
    • 13.1.12. F. Hoffmann-La Roche AG
    • 13.1.13. Gilead Sciences, Inc.
    • 13.1.14. GlaxoSmithKline PLC
    • 13.1.15. Johnson & Johnson
    • 13.1.16. Merck & Co., Inc.
    • 13.1.17. Novartis AG
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. ANTIVIRAL DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIVIRAL DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. ANTIVIRAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ANTIVIRAL DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. ANTIVIRAL DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ANTIVIRAL DRUGS MARKET DYNAMICS
  • FIGURE 7. ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 8. ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2023 VS 2030 (%)
  • FIGURE 10. ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2023 VS 2030 (%)
  • FIGURE 12. ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ANTIVIRAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. ANTIVIRAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. ANTIVIRAL DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. ANTIVIRAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIVIRAL DRUGS MARKET SIZE, BY BRANDED DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ANTIVIRAL DRUGS MARKET SIZE, BY GENERIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 9. ANTIVIRAL DRUGS MARKET SIZE, BY ACQUIRED IMMUNODEFICIENCY SYNDROME THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS (B & C) THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. ANTIVIRAL DRUGS MARKET SIZE, BY HERPES THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. ANTIVIRAL DRUGS MARKET SIZE, BY INFLUENZA THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. ANTIVIRAL DRUGS MARKET SIZE, BY PNEUMONIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 15. ANTIVIRAL DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTRES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 145. ANTIVIRAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 146. ANTIVIRAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. ANTIVIRAL DRUGS MARKET LICENSE & PRICING